IMVT-1401-2501: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD)
Latest Information Update: 05 Feb 2026
At a glance
- Drugs Batoclimab (Primary)
- Indications Graves' disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Immunovant
Most Recent Events
- 05 Feb 2026 Last checked against ClinicalTrials.gov record.
- 02 Feb 2026 Status changed from active, no longer recruiting to completed.
- 03 Sep 2025 According to Immunovant media release, George Kahaly is a lead principal investigator of this study.